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SUMMARY 
Fluorescent VEGF-A isoforms have been evaluated for their ability to discriminate between 
VEGFR2 and NRP1 in real-time ligand binding studies in live cells using BRET.  To enable this, 
single-site (N-terminal cysteine) labelled versions of VEGF165a, VEGF165b and VEGF121a were 
synthesised. These were used in combination with N-terminal NanoLuc-tagged VEGFR2 or NRP1 
to evaluate the selectivity of VEGF isoforms for these two membrane proteins.  All fluorescent 
VEGF-A isoforms displayed high affinity for VEGFR2.  Only VEGF165a-TMR bound to NanoLuc-
NRP1 with a similar high affinity (4.4nM).  Competition NRP1 binding experiments yielded a rank 
order of potency of VEGF165a > VEGF189a > VEGF145a. VEGF165b, VEGF-Ax, VEGF121a and 
VEGF111a were unable to bind to NRP1. There were marked differences in the kinetic binding 
profiles of VEGF165a-TMR for NRP1 and VEGFR2. These data emphasise the importance of the 
kinetic aspects of ligand binding to VEGFR2 and its co-receptors in the dynamics of VEGF 
signalling.		 
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INTRODUCTION 
Angiogenesis, the growth of new blood vessels from pre-existing vasculature, is critical in both 
physiology and pathology for maintaining an adequate supply of oxygen and nutrients (Chung and 
Ferrara, 2011). Vascular endothelial growth factor A (VEGF) is an essential mediator of both 
angiogenesis and vascular permeability that signals via its cognate receptor VEGF Receptor 2 
(VEGFR2) (Koch et al., 2011; Shibuya, 2011). VEGF binds to VEGFR2 at the extracellular 
immunoglobulin (Ig)-like domains 2 and 3 (D2/D3) of the receptor (Ruch et al., 2007). VEGF 
binding stimulates receptor dimerization and initiates conformational changes across the VEGFR2 
dimer interface that result in auto- and trans-phosphorylation of intracellular tyrosine residues 
(Cunningham et al., 1997). Subsequent recruitment of adaptor proteins and activation of 
downstream signalling cascades leads to cell proliferation, migration and survival (Koch et al., 
2011). VEGFR2 is overexpressed in many solid tumours and leads to activation of pro-angiogenic 
signalling which promotes tumourogenesis.  As a consequence, a number of anti-angiogenic 
therapeutics have been targeted at the VEGF/VEGFR2 axis (Ferrara and Adamis, 2016).  
VEGFR2 signalling is selectively enhanced by its co-receptor Neuropilin-1 (NRP1), a 
transmembrane glycoprotein that lacks kinase activity and whose upregulation in malignant 
tumours is correlated to aggressive cancer phenotypes (Jubb et al., 2012; Goel and Mercurio, 
2013; Lee et al., 2014). NRP1 is a multifaceted co-receptor that can also bind structurally and 
functionally unrelated class 3 semaphorins (Djordjevic and Driscoll, 2013; Guo and Vander Kooi, 
2015).  However its functional role in vessel development is evident from the severe cardiovascular 
abnormalities exhibited in Nrp1 knockout mice (Kitsukawa et al., 1997; Kawasaki et al., 1999; Gu 
et al., 2003). NRP1 selectively potentiates VEGFR2-mediated endothelial cell motility and vascular 
permeability without promoting proliferation, driving arterial vessel development in vivo (Chittenden 
et al., 2006; Fantin et al., 2011; Lanahan et al., 2013). While it lacks kinase activity, NRP1 has a 
short cytoplasmic tail containing a Serine-Glutamate-Alanine motif that interacts with PDZ domain-
containing synectin (Cai and Reed, 1999; Wang et al., 2006; Prahst et al., 2008), through which 
NRP1 may modulate VEGFR2 trafficking or expression (Ballmer-Hofer et al., 2011). VEGF 
interacts with NRP1 via a C-terminal arginine residue, whereas N-terminal residues on VEGF are 
responsible for VEGFR2 binding (Djordjevic and Driscoll, 2013; Guo and Vander Kooi, 2015).  
VEGF is an anti-parallel disulphide-linked homodimer with multiple endogenous isoforms resulting 
from alternative mRNA splicing or encoded by separate genes which each elicit different signalling 
outcomes (Woolard et al., 2009). Alternative splicing of the VEGF-A gene (Vegfa) results in 
isoforms of varying lengths that include the prototypical pro-angiogenic isoform VEGF165a and a 
freely diffusible VEGF121a isoform lacking interactions with heparin (Harper and Bates, 2008). 
Isoforms with a carboxy-terminus substituting CDKPRR for SLTRKD, including VEGF165b and the 
more recently identified VEGF-Ax, have reported anti-angiogenic activity in vivo (Woolard et al., 
2004; Cébe Suarez et al., 2006; Eswarappa et al., 2014). Distinct signalling outcomes downstream 
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of VEGFR2 have been suggested to result from different abilities of distinct VEGF isoforms to bind 
to NRP1 (Simons et al., 2016; Peach et al., 2018). Despite existing anti-cancer therapeutics 
targeting VEGF and its known modulation by NRP1, there is limited quantitative information on the 
binding characteristics of specific isoforms at full length VEGFR2 and NRP1 in living cells.  
Significant advances in our understanding of ligand binding to G-protein coupled receptors 
(GPCRs), and more recently RTKs, have resulted from the development of fluorescent ligand 
technologies that use bioluminescence resonance energy transfer (BRET) (Stoddart et al., 2015; 
Stoddart et al., 2018). NanoBRET is a proximity-based assay that can quantify interactions 
between a fluorescent ligand and a receptor fused at its N-terminus to a small, bright 
Nanoluciferase (NanoLuc) (Machleidt et al., 2015; Stoddart et al., 2015; Kilpatrick et al., 2017). 
Having developed a technique to stoichiometrically label VEGF165a with the red-shifted fluorophore 
tetramethylrhodamine (TMR) (Kilpatrick et al., 2017), we synthesised fluorescent variants of ‘anti-
angiogenic’ VEGF165b and freely diffusible VEGF121a to probe their pharmacology at full-length 
VEGFR2 and its co-receptor NRP1 in living cells at 37°C.  We report here the binding affinities and 
real-time binding kinetics of VEGF-A isoforms to NanoLuc-tagged VEGFR2 and NRP1.  We also 
demonstrate that fluorescent analogues of VEGF165b and VEGF121a can be used to selectively bind 
to VEGFR2 but not NRP1 in living cells. 
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RESULTS 
Generation and characterization of stoichiometrically labelled VEGF165b-TMR and VEGF121a-
TMR. 
Synthesis and purification of fluorescent VEGF-A isoforms VEGF165b and VEGF121a (Figure 1a) 
labelled at a single N-terminal cysteine residue with 6-TMR-PEG-CBT, were prepared as 
described by Kilpatrick et al. (2017). Briefly, VEGF isoforms were expressed as secreted N 
terminal HaloTag fusions. The linker connecting HaloTag and the VEGF isoforms contained a 
modified TEV recognition site (EDLYFQC), which upon proteolytic cleavage released a VEGF 
isoform with an N terminal cysteine residue that can be specifically labelled via 2-
cyanobenzothiazole (CBT) condensation. 
Labelling specificity of VEGF165b-TMR (Figure S1) and VEGF121a-TMR (Figure S2) were 
determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of labelled 
and unlabelled VEGF isoforms that were digested with multiple proteases as described previously 
for VEGF165a-TMR (Kilpatrick et al., 2017). This analysis indicated highly efficient and selective 
labeling of the N terminal cysteine residue of each VEGF isoform (Figures S1 and S2).  6-TMR-
PEG-CBT chemical modification (817 Da) was identified exclusively on the N-terminal cysteine 
residue of each VEGF isoform at 97% (VEGF165b-TMR) and 94-99% (VEGF121a-TMR) labeling 
efficiency (Tables S1 and S2). We did not observe non-specific labeling of any of the other 
cysteine residues present in either VEGF165b-TMR or VEGF121a-TMR. Fluorescence SDS-PAGE 
analysis of the purified VEGF165b-TMR and VEGF121a-TMR isoforms in the presence or absence of 
100 mM dithiothreitol (DTT) confirmed that, in non-reducing conditions, both VEGF isoforms were 
largely present as homodimers (Figures S1 and S2). Deglycosylation by PNGase provided 
evidence that the purified VEGF165b-TMR was glycosylated (Figure S1).  However, for VEGF121a-
TMR, treatment with PNGase strongly suggested that it was present in both glycosylated and non-
glycosylated forms under normal conditions (Figure S2).  To confirm the concentrations of 
VEGF165b-TMR and VEGF121a-TMR (and their dimeric nature), we also undertook fluorescence 
correlation spectroscopy studies in the presence and absence of 10mM DTT as described by 
Kilpatrick et al (2017) (Figures S1 and S2). 
Agonist activity of fluorescent VEGF-isoforms in HEK293 cells and HUVECs. 
To determine whether the N-terminal TMR labelling of VEGF165b and VEGF121a influenced their 
VEGFR2 agonist activity, a calcium-based NFAT reporter gene assay (Carter et al., 2015) was 
used to measure signalling downstream of wild-type VEGFR2 expressed in HEK293 cells lacking 
VEGFR1 or NRP1 (Figure S3).  Figure 1 shows the agonist activity of VEGF165b-TMR (Figure 1b) 
and VEGF121a-TMR (Figure 1c) compared to the agonist actions of equivalent unlabelled VEGF 
isoforms prepared in an identical manner to the fluorescent variant.  Each ligand evoked a sub-
maximal response compared to the response obtained with 10nM VEGF165a (Figure 1b,c) 
consistent with previous work with unlabelled VEGF165b and VEGF121a (Carter et al., 2015; 
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Kilpatrick et al., 2017).  However, a comparison of the EC50 values of VEGF165b-TMR and 
VEGF121a-TMR indicated that the fluorescent ligands had EC50 values that were an order of 
magnitude higher than their unlabelled counterparts (VEGF165b-TMR pEC50=8.28 ± 0.74 vs. 
VEGF165b pEC50=9.16 ± 0.09; VEGF121a-TMR pEC50=8.57 ± 0.07 versus VEGF121a pEC50=9.51 ± 
0.09; n=5 in each case). However, in each case the TMR-labelled VEGF isoform produced a 
similar maximum response to that obtained with the unlabelled VEGF165b or VEGF121a (Figure 
1b,c).  Although untransfected HEK293T cells did show some low level expression of endogenous 
VEGFR2 (Figure S3), neither untransfected or NanoLuc-NRP1-expressing cells produced a 
measurable NFAT signal in response to VEGF165a (data not shown). 
The agonist effect of the two fluorescent ligands was also evaluated for pY1212 phosphorylation of 
VEGFR2 using a phosphospecific antibody (Figure 1c,d).  At 30nM, both ligands were able to 
stimulate pY1212 phosphorylation to the same extent as the equivalent unlabelled versions of 
VEGF165b and VEGF121a (Figure 1c,d).  
Finally, we also investigated agonist activity of these VEGF-A isoforms in human umbilical vein 
endothelial cells (HUVECs) that endogenously express both VEGFR2 and NRP1 (Figure S3; 
Figures 1c,d).  Immunolabelling of HUVECs showed a minimal presence of endogenous VEGFR1 
(Figure S3).  Both unlabelled isoforms stimulated a concentration-dependent increase in HUVEC 
cell proliferation (Figures 1e,f).  VEGF165b produced a maximum response that was only circa 60% 
of that obtained with 3nM VEGF165a (Figure 1e).  In contrast, VEGF121a produced a similar 
response to that obtained with VEGF165a (Figure 1f).  Both fluorescent ligands, however, evoked 
much lower maximal responses (30% for VEGF165b-TMR; 40% for VEGF121a-TMR) than those 
obtained with their unlabelled counterparts (Figures 1e,f) indicative of partial agonist activity.  In 
keeping with this, the EC50 values of the fluorescent isoforms for HUVEC cell proliferation were, 
however, very similar to the unlabelled VEGF165b and VEGF121a (Figures 1e,f).  This contrasted 
markedly to the full agonist response determined previously with VEGF165a-TMR in HUVECs 
(Kilpatrick et al., 2017). 
Binding of VEGF165a-TMR, VEGF165b-TMR and VEGF121a-TMR to VEGFR2. 
Initial imaging studies were undertaken to monitor the spatial aspects of VEGF isoform binding to 
HaloTag-labelled VEGFR2 expressed in HEK293T cells (labelled with membrane-impermeant 
HaloTag-AlexaFluor488 substrate; Figure 2).  Under basal conditions, VEGFR2 was located on 
both the cell membrane and within intracellular sites (indicative of constitutive internalisation; 
Kilpatrick et al., 2017; Figure 2).  Following 60 minute stimulation with 10nM VEGF165a-TMR 
(Kilpatrick et al., 2017), VEGF165b-TMR or VEGF121a-TMR, there was a clear co-localisation with 
HaloTag-VEGFR2 at both the cell membrane and increased internalised receptor (Figure 2). 
NanoBRET was also used to quantify the real-time binding of the three fluorescent VEGF-A 
isoforms to NanoLuc-tagged VEGFR2 expressed in living HEK293T cells at 37°C. The assay is 
based on the close proximity (<10nm) required for bioluminescence energy transfer between the 
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fluorophore of a receptor-bound fluorescent ligand (BRET acceptor) and the N-terminal NanoLuc 
(BRET donor) of the receptor.  Saturable binding of VEGF165a-TMR, VEGF165b-TMR and 
VEGF121a-TMR to NanoLuc-VEGFR2 was clearly demonstrated and this was largely prevented in 
the presence of 100nM unlabelled competitor (Figure 3a,b,c).  Derived equilibrium binding 
constants revealed that each isoform bound with nanomolar affinity with a rank order VEGF165a-
TMR > VEGF121a-TMR > VEGF165b-TMR (Table 1). Real-time binding kinetics measured every 30 
seconds at 37°C showed VEGFR2 binding peaked within 20 minutes for each VEGF-TMR isoform 
(Figure 3d,e,f).  Kinetic binding experiments were conducted with 5 separate concentrations of 
VEGF-TMR isoform which enabled a global fit of the data to provide estimates for kon and koff for 
each fluorescent ligand.  These data showed that VEGF165a-TMR had a faster Kon than VEGF121a-
TMR and VEGF165b-TMR but each isoform had similar Koff rates (Table 1).  The ratio of koff/kon also 
provided an estimate of the kinetically derived KD values which were very similar to those obtained 
from equilibrium measurements (Table 1). 
To gain some insight into whether NanoLuc-VEGFR2 or HaloTag-VEGFR2 were markedly 
overexpressed in our HEK293T cells, we compared their relative expression levels to native 
untransfected HEK293T and HUVECs using quantitative immunohistochemistry with a selective 
VEGFR2 antibody (Figure S4).  These data showed that the expression levels of the tagged 
VEGFR2 variants were low and below the native expression level of VEGFR2 in HUVECs (Figure 
S4). 
Using VEGF165a-TMR, VEGF165b-TMR and VEGF121a-TMR as three distinct fluorescent probes, 
increasing concentrations of unlabelled VEGF-Ax were used to inhibit the specific binding of each 
concentration of fluorescent ligand to NanoLuc-VEGFR2 (0.25-3nM) (Figure 3g,h,i).  These data 
were used to derive pKi values for VEGF-Ax assuming mass action interactions (Table S3).  
Binding affinities were also derived from similar experiments with a comprehensive panel of 
unlabelled VEGF-A isoforms at NanoLuc-VEGFR2 (Table S3).  pKi values obtained for each 
competing ligand were not significantly different between the fluorescent VEGF probes used (one-
way ANOVA).  
Real-time binding of fluorescent VEGF165a to NRP1. 
We were also able to apply the NanoBRET technology to the type I single transmembrane co-
receptor NRP1. NanoLuc was fused to the extracellular N-terminus of NRP1 and expressed in 
HEK293T cells to isolate binding of the different fluorescent VEGF-A isoforms to full-length NRP1.  
Specific binding of VEGF165a-TMR to NanoLuc-NRP1 was clearly observed with minimal non-
specific binding following incubation for 60 min (KD=4.41 ± 1.34nM, n=5; Figure 4a).  Kinetic 
binding measurements also revealed that specific binding of VEGF165a-TMR to NanoLuc-NRP1 
was reached within 4 minutes and exhibited faster kon (7.11 ±  2.33 x107min-1.M-1) and koff (0.26 ± 
0.05 min-1) rate constants than were achieved with this ligand at NanoLuc-VEGFR2 (Figure 4b; 
Table 1).  However, the equilibrium dissociation constants were very similar for VEGF165a-TMR 
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between NRP1 and VEGFR2 (Table 1).  Displacing each concentration of VEGF165a-TMR (0.5 - 
5nM) by increasing concentrations of unlabelled VEGF165a showed competitive inhibition, yielding 
a pKi of 9.54 ± 0.21 (Figure 4c; n=5; Table S3). A linear relationship was observed between the 
IC50 and VEGF165a-TMR concentration at NanoLuc-NRP1 (R2=0.95, p<0.005; Figure 4d).  
NRP1 expressed in living cells does not bind VEGF165b, VEGF121a, VEGF-Ax or VEGF111a. 
To investigate how the three distinct fluorescent VEGF isoforms interacted with NRP1, we used 
VEGF165a-TMR alongside VEGF165b-TMR and VEGF121a-TMR to image fluorescent ligand binding 
to HaloTag-NRP1 expressed in HEK293 cells and labelled with membrane-impermeant 
AlexaFluor488. Upon both vehicle and fluorescent ligand application, HaloTag-NRP1 remained at 
the cell surface (Figure 5a). While 10nM VEGF165a-TMR colocalised with HaloTag-NRP1 when 
imaged after 60 minutes, no binding of VEGF165b-TMR and VEGF121a-TMR to HaloTag-NRP1 was 
detected (Figure 5a).  This latter observation was confirmed using NanoBRET, where no saturable 
binding was detected between VEGF165b-TMR or VEGF121a-TMR and NanoLuc-NRP1 (Figure 5b). 
Using 3nM VEGF165a-TMR as a fluorescent probe, only unlabelled VEGF165a, VEGF145a and 
VEGF189a displaced binding from NRP1 (Figure 5c).  Full competition ligand binding experiments 
allowed pKi values at NanoLuc-NRP1 to be determined for these latter VEGF-A isoforms (Table 
S3).  Quantitative immunohistochemistry analysis confirmed that NanoLuc-NRP1 and HaloTag-
NRP1 were expressed at low levels in HEKT293 cells (Figure S4). 
NanoBRET was also used to investigate ligand binding at a previously identified VEGF binding-
dead mutant NRP1 Y297A, lacking a key residue in the b1 domain responsible for VEGF binding 
(Fantin et al., 2014). Having also confirmed membrane expression of HaloTag-NRP1 Y297A using 
live cell imaging, colocalisation was absent for all three fluorescent VEGF isoforms (Figure 6a).  
Analogous BRET experiments showed VEGF165a-TMR did not interact with NanoLuc-NRP1 Y297A 
yielding BRET ratios that did not differ from vehicle (Figure 6b). This confirmed NRP1 Y297A as a 
mutant deficient for VEGF binding.  
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DISCUSSION 
In the present study we have evaluated the ability of three fluorescent analogues of VEGF 
(VEGF165a, VEGF165b and VEGF121a) to discriminate between VEGFR2 and NRP1 in living cells in 
real time.  To enable this, single-site (N-terminal cysteine) labelled versions of VEGF165b and 
VEGF121a were prepared essentially as described previously for VEGF165a (Kilpatrick et al., 2017).  
These fluorescent ligands were used in combination with HEK293T cells stably expressing N-
terminal NanoLuc-tagged VEGFR2 or NRP1 to evaluate the selectivity of VEGF isoforms for these 
two membrane proteins.  The close proximity requirements (<10nm) of the interaction between 
fluorescent ligand and receptor protein in order for bioluminescence transfer to occur (for 
NanoBRET measurement) ensured a high specificity of interaction, regardless of the extent of 
endogenous receptor expression. This was important since, although HEK293T did not express 
endogenous NRP1 (Figure S3), endogenous VEGFR2 were detected in a subpopulation of un-
transfected HEK293T cells.  Furthermore, following expression of HaloTag-labelled NRP1, the 
endogenous expression of VEGFR2 appeared to increase (Figure S3).  The expression level of 
VEGFR1 was, however, minimal in both untransfected HEKT293 cells and those transfected with 
tagged-variants of either VEGFR2 or NRP1. 
VEGF165a-TMR, VEGF165b-TMR and VEGF121a-TMR each exhibited saturable binding to NanoLuc-
VEGFR2 expressed in HEK293T cells with nanomolar affinity. Furthermore there were minimal 
levels of non-specific binding detected with each fluorescent ligand. Analysis of the real-time 
binding characteristics of each fluorescent ligand indicated that all three fluorescent VEGF variants 
had very similar kon and koff rate constants and indeed their off rates were very slow (koff = 0.05-
0.06 min-1).  pKi values were obtained for a panel of seven unlabelled VEGF-A isoforms, including 
the recently described VEGF-Ax (Eswarappa et al., 2014), from competition experiments using all 
three of the fluorescent probes. All seven ligands had comparable nanomolar binding affinities for 
VEGFR2 ranging between 0.2-1.4nM in agreement with previous studies (Peach et al., 2018), 
suggesting that potential differences in signalling responses of these isoforms is not due to binding 
alone (Whitaker et al., 2001; Cébe Suarez et al., 2006; Eswarappa et al., 2014; Kilpatrick et al., 
2017).  There was no evidence of probe dependence in the measurement of these equilibrium 
constants suggesting that the interactions could be described be simple mass action interactions.   
VEGF165a-TMR bound to NanoLuc-NRP1 in living cells with a similar high affinity (4.41nM) to that 
observed at NanoLuc-VEGFR2 (2.03nM).  However in marked contrast, VEGF165b-TMR and 
VEGF121a-TMR did not bind to NanoLuc-NRP1 (measured via NanoBRET) at concentrations up to 
20nM. This observation was corroborated by live cell confocal imaging that showed that VEGF165b-
TMR (10nM) and VEGF121a-TMR (10nM) bound to HaloTag-VEGFR2 but not to HaloTag-NRP1. 
The importance of residue Y297 (Fantin et al., 2014) of NRP1 for the binding of VEGF165a was 
confirmed in HEK293T cells expressing a Y297A mutant of NRP1. Competition binding 
experiments at NanoLuc-NRP1 yielded a rank order of pKi values of VEGF165a > VEGF189a > 
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VEGF145a. In contrast, VEGF165b, VEGF-Ax, VEGF121a and VEGF111a were unable to displace 3nM 
VEGF165a-TMR at concentrations up to 30nM. These observations support previous reports that 
these isoforms may be unable to bind NRP1 (Woolard et al., 2009).  There have, however, been 
conflicting reports regarding VEGF121a binding to NRP1 (reviewed in Sarabipour and Mac 
Gabhann, 2017).  Thus, although radioligand binding and solid-phase biotinylation assays have 
shown no interaction between VEGF121a and NRP1 (Cébe Suarez et al., 2006; Kawamura et al., 
2008; Xin et al., 2016), low affinity binding was detected using immobilised monomeric NRP1 and 
surface plasmon resonance (SPR) or isolated NRP1 b1/b2 domains (Pan et al., 2007; Parker et 
al., 2012; Delcombel et al., 2013).   
A key feature of the present study is the ability to study the binding of VEGF-A isoforms to full 
length VEGFR2 and NRP1 in living cells and in real time.  This ensures that the interactions 
studied are of physiological relevance (Djordjevic and Driscoll, 2013). The lack of binding of 
VEGF165b, VEGF-Ax, VEGF121a and VEGF111a to NRP1 is seen at concentrations up to 20nM, 
which are far in excess of the predicted physiological levels of these ligands (<1nM; Clegg and 
Mac Gabhann, 2017).  These data suggest that VEGF165b-TMR and VEGF121a-TMR can be used 
as selective fluorescent probes for VEGFR2, even in cells that also express endogenous NRP1. 
Real-time analysis of the binding of VEGF165a-TMR to NanoLuc-NRP1 expressed in HEK293T 
cells enabled the kinetics of ligand-binding to be monitored to these membrane proteins for the first 
time. Despite comparable equilibrium dissociation constants determined by saturation and kinetic 
binding experiments, VEGF165a-TMR had faster binding kinetics at NRP1 compared to VEGFR2.  
Maximum specific binding to NanoLuc-NRP1 could be achieved within 5 min largely as a 
consequence of its very fast koff (0.26 min-1). These data suggest that in cells expressing both 
VEGFR2 and NRP1, VEGF165a will bind more quickly to NRP1 than to VEGFR2, particularly at low 
agonist concentrations.  This may have important implications for the dynamics of VEGF signalling 
and emphasise the need to understand the kinetic aspects of ligand binding to VEGFR2 and its co-
receptors, as well as the temporal aspects of intracellular signalling. Thus, since: 
      !!! = !.!"#!!" ! ! ! !!""    
for 1nM VEGF165a-TMR using the parameters provided in Table 1 of our manuscript, the t1/2  for 
association to VEGFR2 will be 9.2 min whilst that for NRP1 will be 2.1 min.  For 10nM VEGF165a-
TMR the t1/2 values are 3.2 min and 0.7 min for VEGFR2 and NRP1 respectively. 
Imaging ligand/receptor interactions using a membrane-impermeant HaloTag label also highlighted 
distinct differences in the subcellular distributions of VEGFR2 and NRP1, and the consequences of 
incubation with VEGF165a. HaloTag-VEGFR2 was constitutively internalised in the absence of 
ligand stimulation.  This agrees with previous antibody-based imaging in HUVECs and HMVECs 
(Gampel et al., 2006; Basagiannis and Christoforidis, 2016; Basagiannis et al., 2016), and our own 
studies using VEGFR2 stably expressed in HEK293 cells (Kilpatrick et al., 2017).  Furthermore, 
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VEGF165a-TMR, VEGF165b and VEGF121a were able to stimulate VEGFR2 internalization.  In 
contrast, HaloTag-NRP1, labelled with a cell impermeant HaloTag dye, was largely expressed on 
the cell membrane of HEK293T cells and remained at the cell surface despite 60 min stimulation 
with a high concentration of VEGF165a-TMR. Furthermore, VEGF165a-TMR only labelled membrane 
expressed NRP1.  Other groups have shown an intracellular NRP1 distribution using 
permeabilised fluorescent antibody labelling (Narazaki and Tosato, 2006; Ballmer-Hofer et al., 
2011).   However, it is clear from the present work that cell membrane NRP1 is the primary target 
for VEGF165a and that this VEGF-A isoform does not stimulate internalisation of NRP1. 
It has been previously noted that fluorescent ligands can have very different pharmacological 
properties to their un-labelled counterparts and that they should be evaluated as new chemical 
entities (Stoddart et al., 2015, 2016). We have previously shown that VEGF165a-TMR behaves very 
similarly to VEGF165a in its ability to (a) stimulate NFAT reporter gene responses in HEK293T cells 
expressing wild-type VEGFR2 and (b) proliferation of HUVEC cells (Kilpatrick et al., 2017).  
However, both VEGF165b-TMR and VEGF121a-TMR behave differently in functional assays to 
VEGF165b and VEGF121a prepared in an identical way to the fluorescent probes.  Thus, in NFAT 
assays the EC50 values obtained with both VEGF165b-TMR (pEC50=8.28) and VEGF121a-TMR 
(pEC50=8.57) were an order of magnitude higher (less potent) than the non-fluorescent versions.  
However, these EC50 values were very similar to the pKD values obtained from saturation binding 
studies (7.9 - 8.1 for VEGF165b-TMR and 8.2 – 8.4 for VEGF121a-TMR) and from competition 
binding studies (9.29 – 9.30 for VEGF165b and 9.16 – 9.59 for VEGF121a).  This suggests that the 
differences were predominantly affinity based and that there was little signal amplification in the 
NFAT assay.  Comparison of the agonist effects of fluorescent VEGF165b and VEGF121a on 
pY1212 phosphorylation, however, indicated that they produced the same maximal response as 
their unlabelled counterparts.  In the HUVEC cell proliferation assay both VEGF165b-TMR and 
VEGF121a-TMR appeared to be of lower efficacy than the non-fluorescent ligands but still showed 
partial agonism in stimulating HUVEC prolifieration.   Taken together, these data suggest that 
VEGF165b-TMR and VEGF121a-TMR, unlike VEGF165a-TMR, are lower affinity and lower efficacy 
agonists at VEGFR2 than their unlabelled analogues.  Furthermore, the extent of agonist activity 
appears to depend on the signalling pathway being monitored.  This may point to an ability for 
these fluorescent analogues to exhibit some signalling bias in a similar way to that seen with G 
protein-coupled receptors (Smith et al., 2018). 
In summary, fluorescent VEGF isoforms were used to probe the pharmacology of VEGFR2 and its 
co-receptor NRP1 in living cells in real-time at 37°C. Despite approved therapeutics targeting 
VEGF/VEGFR2 (Ferrara and Adamis, 2016), this is the first comprehensive ligand binding study of 
the interactions of a range of VEGF isoforms with both full-length VEGFR2 and NRP in living cells. 
The real-time sensitivity of NanoBRET revealed clear differences in the kinetic binding profiles of 
VEGF165a-TMR for NRP1 and VEGFR2, despite this ligand having a very similar equilibirum 
dissociation binding constant for each membrane protein.  All VEGF isoforms studied had a similar 
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high affinity for VEGFR2 but not all isoforms interacted with NRP1.  In particular, VEGF165b-TMR 
and VEGF121a-TMR were not able to bind to NRP1 at physiologically relevant concentrations.  
These two partial agonist ligands should therefore be important and selective probes for the study 
of VEGFR2 in cells also expressing NRP1.  Furthermore, our study also emphasises the 
importance of the kinetic aspects of ligand binding to VEGFR2 and its co-receptors in the overall 
dynamics of VEGF signalling.   
SIGNIFICANCE. 
VEGF-A is an essential mediator of angiogenesis that signals via VEGFR2.  We have synthesised  
fluorescent VEGF-A isoforms and demonstrate that they can discriminate between VEGFR2 and 
its co-receptor NRP1 in real-time ligand binding studies.  We have used a precision chemical 
biology approach in live cells to accurately define the binding characteristics of specific VEGF-A 
isoforms and to determine which isoforms can bind to NRP1 at concentrations required to occupy 
VEGFR2.  Only VEGF165a, VEGF145a and VEGF189a are able to also bind to NRP1. Furthermore, 
we have shown that whilst VEGF165a-TMR has a similar equilibrium binding affinity for VEGFR2 
and NRP1, it binds more rapidly to NRP1 than to VEGFR2.  We have also shown that VEGF165a-
TMR has a shorter residence time (1/koff) at NRP1 (3.8 min) than VEGFR2 (16.6 min).  These 
fluorescent ligands should therefore serve as valuable probes to interrogate the roles of VEGFR2 
and NRP1 in angiogenesis and signalling.  
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Figure legends. 
Figure 1. Functional characterisation of VEGF165b-TMR and VEGF121a-TMR activities. (a) 
Schematic illustrating exons present in different VEGF-A isoforms following alternative mRNA 
splicing, including the region from post-translational readthrough (PTR) in VEGF-Ax. (b) NFAT 
production in HEK293T cells stably expressing wild type VEGFR2 in response to 5 hours 
stimulation with VEGF165b-TMR or VEGF165b prepared identically to the fluorescent analogue, or 
(c) VEGF121a-TMR or unlabelled equivalent VEGF121a. Data are mean ± S.E.M. (5 independent 
experiments, duplicate wells)  expressed as a percentage of the response to 10nM VEGF165a 
measured in the same experiment. (d) VEGFR2 phosphorylation in HEK293T cells stably 
expressing NanoLuc-VEGFR2 in response to 20 minute stimulation with 30nM unlabelled 
VEGF165b or (e) VEGF121a.  Data are presented for  VEGF165b or VEGF121a obtained from a 
commercial source (R&D Systems) or prepared identically to the TMR analogues (Analogue), or 
for the fluorescent TMR-labelled variants of each VEGF-A isoform. As a negative control, cells 
were pre-incubated with 1µM cediranib for 30 minutes and stimulated in its presence. Cells were 
fixed (3% PFA/PBS), permeabilised (0.025% Triton-X-PBS), blocked for non-specific binding, 
incubated with an antibody specific for phosphorylated tyrosine 1212 and nuclei stained with 
H33342. Cells were imaged using an IX Micro widefield platereader (20X objective) and quantified 
using a granularity algorithm (MetaXpress, Molecular Devices). Data were baseline-corrected for 
non-specific binding (secondary antibody only) and expressed as a percentage normalised to 
cediranib-treated wells (0%) and response to 30nM VEGF165a (100%) from 5 independent 
experiments. Statistical analyses was performed using a one-way ANOVA and Sidak’s multiple 
comparisons showed no significance. (f, g) Comparison of the extent of HUVEC proliferation in 
response to stimulation with VEGF165b or VEGF165b-TMR (f) and VEGF121a or VEGF121a-TMR (g) 
isoforms. Following serum deprivation, HUVECs were stimulated in duplicate wells for 48 hours 
with 0.3, 3 or 30 nM ligand (37°C/5% CO2), then fixed using 3% PFA/PBS and nuclei stained with 
H33342. Cells were imaged using an IX Micro widefield platereader (4X objective) with nuclei 
counted using a granularity algorithm (MetaXpress, Molecular Devices). Data are expressed as a 
percentage of the response to 3nM VEGF165a  and represent mean ± S.E.M. from 6 independent 
experiments. Statistical analyses were performed using a one-way ANOVA and Sidak’s multiple 
comparisons: * p<0.05. See also Figure S1, S2 and Table S1 and Table S2. 
Figure 2. Colocalisation of fluorescent VEGF-A isoform binding and HaloTag-VEGFR2. 
Confocal images of HEK293T cells stably expressing HaloTag-VEGFR2 (green) stimulated with 
vehicle or 10nM VEGF165a-TMR, VEGF165b-TMR or VEGF121a-TMR (red) for 1 hour at 37°C. Cells 
were imaged live using a Zeiss LSM710 and are representative images of 3 independent 
experiments (scale bar 10µm). See all Figure S3 and S4. 
Figure 3. Binding characteristics of fluorescent VEGF isoforms to NanoLuc-VEGFR2 
expressed in HEK293 cells.  (a,b,c) HEK293T cells expressing N-terminal NanoLuc-VEGFR2 
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were incubated with increasing concentrations of (a) VEGF165a-TMR, (b) VEGF165b-TMR or (c) 
VEGF121a-TMR, in the presence and absence of 100nM unlabelled VEGF, added simultaneously 
to define non-specific binding (60 minutes; 37°C). BRET ratios are expressed as mean ± S.E.M. 
from 5 independent experiments with duplicate wells.  Where not shown error bars are within the 
size of the symbol. (d,e,f) Time course of (d) VEGF165a-TMR, (e) VEGF165b-TMR or (f) VEGF121a-
TMR ligand binding kinetics at NanoLuc-VEGFR2. Cells treated with furimazine were left to 
equilibrate for 5 minutes before addition of 1-20nM fluorescent VEGF ligand or vehicle and 
measurements were taken every 30 seconds for 20 minutes (37°C). Baseline BRET ratios are 
corrected to vehicle at time zero. Data represent mean ± S.E.M from 5 independent experiments 
and individual curves were fitted with a simple exponential association model. (g,h,i) Displacement 
of (g) VEGF165a-TMR, (h) VEGF165b-TMR or (i) VEGF121a-TMR binding by unlabelled VEGF-Ax. 
Increasing concentrations of VEGF-Ax were added in duplicate wells simultaneously with 5 
separate fixed concentrations (0.25-3nM) of VEGF165a-TMR, VEGF165b-TMR or VEGF121a-TMR 
(60 minutes, 37°C). Raw BRET ratios from 5 independent experiments are shown as mean ± 
S.E.M. with bars illustrating vehicle (white bars) or fluorescent VEGF-TMR alone.  
Figure 4. Binding characteristics of VEGF165a binding to NanoLuc-NRP1.  (a) Increasing 
concentrations of VEGF165a-TMR were added to HEK293T cells stably expressing N-terminal 
NanoLuc-NRP1 in the presence and absence of 100nM unlabelled VEGF165a to determine non-
specific binding and cells were incubated for 60 minutes at 37°C. Raw BRET ratios are expressed 
as mean ± S.E.M. from 5 independent experiments. (b) Time course of VEGF165a-TMR binding to 
NanoLuc-NRP1. BRET ratios were baseline-corrected to vehicle, curves were fitted to a simple 
exponential association model and data are shown as mean ± S.E.M from 5 independent 
experiments.  (c) Inhibition of the binding of VEGF165a-TMR (0.5,1, 2, 3 and 5nM) to NanoLuc-
NRP1 by increasing concentrations of unlabelled VEGF165a added simultaneously and incubated 
for 60 minutes at 37°C. Raw BRET ratios from 5 independent displacement experiments using 
duplicate wells are shown as mean ± S.E.M. with bars representing vehicle (white) or VEGF165a-
TMR only.  (d) Linear regression analysis (R2 = 0.95; p<0.005) of the relationship between IC50 
values determined in (c) and VEGF165a-TMR concentration. The y intercept provides an estimate 
for the Ki of competing VEGF165a (0.10nM), while the slope (0.09) represents the ratio Ki/KD thus 
yielding an estimated KD=1.11nM for VEGF165a-TMR at NanoLuc-NRP1.  
Figure 5. Selective binding of VEGF isoforms at NRP1.  (a) Confocal live cell imaging of 
fluorescently labelled VEGF-TMR isoforms binding to N-terminal HaloTag-NRP1 stably expressed 
in HEK293T cells.  HaloTag-NRP1 was tagged with the membrane-impermeant HaloTag-AF488 
dye (green) and then incubated with 10nM VEGF165a-TMR, VEGF165b-TMR or VEGF121a-TMR 
(red) for 60 minutes at 37°C. Cells were imaged using an LSM710 confocal microscope and 
images are representative of those obtained in 3 independent experiments (scale bar 10µm).  (b) 
NanoLuc-NRP1 HEK293 cells were incubated with increasing concentrations of VEGF165a-TMR, 
VEGF165b-TMR or VEGF121a-TMR and incubated for 60 minutes at 37°C. Raw BRET ratios are 
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expressed as mean ± S.E.M. from 3-4 independent experiments. (c) Inhibition of VEGF165a-TMR 
(3nM) by competing unlabelled VEGF isoforms (30nM), added simultaneously and incubated for 
60 minutes at 37°C. Data are normalised to 3nM VEGF165a-TMR (100%, black bar) and represent 
mean ± S.E.M pooled from 5 independent experiments. Statistical analyses were performed using 
a Welch’s t test: **** p≤0.0001. 
Figure 6. The NRP1 mutant Y297A is unable to bind any VEGF isoforms.  (a) Live confocal 
imaging of HEK293T cells stably expressing mutant HaloTag-NRP1 Y297A (green) labelled with 
membrane-impermeant HaloTag-AF488 dye (green). Cells were stimulated with 10nM VEGF165a-
TMR, VEGF165b-TMR or VEGF121a-TMR for 60 minutes at 37°C. Cells were imaged using an 
LSM710 confocal microscope and images are representative images of 3 independent 
experiments (scale bar 10µm).  (b) NanoBRET measurements of the effect of unlabelled VEGF 
isoforms (30nM) on the binding of 3nM VEGF165a-TMR to wild type NanoLuc-NRP1 or NanoLuc-
NRP1 Y297A stably expressing HEK293T for 60 minutes (37°C). Raw BRET ratios are expressed 
as mean ± S.E.M. pooled from 4 independent experiments. 
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Table 1.  Binding characteristics of fluorescent ligands binding to VEGFR2 or NRP1. 
Fluorescent 
ligand 
Receptor Saturation 
Kd (nM) 
Kinetic Kd (nM) Kon (min-1M-1) Koff (min-1) 
VEGF165a-TMR NanoLuc-VEGFR2 2.03 ± 0.51 6.64 ± 4.37 1.54x107 ± 0.38x107 0.06 ± 0.02 
VEGF165b-TMR NanoLuc-VEGFR2 9.53 ± 1.36 11.3 ± 3.54 7.29x106 ± 1.84x106 0.06 ± 0.01 
VEGF121a-TMR NanoLuc-VEGFR2 5.54 ± 1.34 5.75 ± 0.46 8.51x106 ± 0.81x106 0.05 ± 0.00 
VEGF165a-TMR NanoLuc-NRP1 4.41 ± 1.34 4.95 ± 1.25 7.11x107 ± 2.33x107 0.26 ± 0.05 
 
Equilibrium binding parameters for fluorescent VEGF isoforms derived from saturation and kinetic NanoBRET experiments, showing equilibrium 
dissociation (KD), association rate (Kon) and dissociation rate (Koff) constants at NanoLuc-VEGFR2 and NanoLuc-NRP1. Data are expressed as mean ± 
S.E.M determined from 5 independent experiment.   
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STAR Methods 
KEY RESOURCES TABLE  
Attached separately.  
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Stephen J. Hill (stephen.hill@nottingham.ac.uk). 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
HUVECs (obtained from a single newborn male donor) and HEK293T (female) cells were 
transfected and cultured as described in Method Details. 
METHOD DETAILS 
Cell Culture. 
HEK293T cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich, USA) 
supplemented with 10% Fetal Calf Serum (FCS; Sigma-Aldrich, USA) at 37°C/5% CO2. Cells were 
passaged at 70-80% confluency using Phosphate Buffered Saline (PBS; Lonza, Switzerland) and 
trypsin (0.25% w/v in versene; Lonza). Stable and transient transfections were performed using 
FuGENE HD (Promega Corporation, USA) at a reagent to cDNA ratio of 3:1. Human umbilical vein 
endothelial cells (HUVECs; C0035C, Thermo Fisher Scientific, USA) were grown at 37°C/5% CO2 
in Medium 200 containing 10% Large Vessel Endothelial Supplement (LVES, 50X; Thermo Fisher 
Scientific, USA) and passaged at 80-90% confluency between passages 4 to 9. 
DNA Constructs. 
For N terminal NanoLuc tagged wildtype VEGFR2 (NM_002253; Genscript, New Jersey, USA) or 
NRP1 constructs (NM_003873.5; Kazusa DNA Research Institute (Japan) the appropriate cDNA 
was cloned into a pF-sNnK CMV/neo vector (Promega Corporation; N1321) encoding the 
secretory signal peptide sequence of IL-6 fused onto the N terminus of NanoLuc. This resulted in 
open reading frames which encoded a secreted NanoLuc fused via a Gly-Ser-Ser-Gly (AIA) linker 
to the N terminus of wildtype VEGFR2 or NRP1 (termed NanoLuc VEGFR2 or NRP1 respectively). 
For N terminal HaloTag constructs, wildtype VEGFR2 or NRP1 cDNA was cloned into a pFN21A 
CMV/neo flexi vector (Promega Corporation; G2821) encoding a fusion of the secretory signal 
peptide sequence of IL-6 onto the N terminus of HaloTag.  The resultant ORFs encoded a 
secreted HaloTag fused via a EPTTEDLYFQSDN(AIA) linker to the N terminus of NRP1 (HaloTag 
VEGFR2 or NRP1). 
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Fluorescent Ligand Synthesis.  
VEGF-A isoforms VEGF165a, VEGF165b and VEGF121a labelled at a single N-terminal cysteine 
residue with 6- tetramethylrhodamine (TMR)-PEG-CBT were synthesised and purified using the 
HaloTag mammalian protein detection and purification system (G6795; Promega Corporation, 
USA) alongside unlabelled analogues prepared identically (as described in Kilpatrick et al., 2017). 
To generate labelled isoforms, the HaloTEV proteolytic release was done in the presence of 
100µM TCEP and 4x molar excess of 6-TMR-PEG-CBT. This step generated VEGF isoform with 
an N-terminal cysteine that served as single point of conjugation with 6-TMR-PEG-CBT. The 
purified labelled isoforms were dialyzed for 24 hours (50mM HEPES, 150mM NaCl) to remove the 
unconjugated 6-TMR-PEG-CBT and TCEP and stored in 2.5mg/ml protease-free bovine serum 
albumin (BSA; Millipore, USA) at -80 0C. Labelling specificity and efficiency was determined using 
liquid chromatography-tandem mass spectrometry (LC-MS).  SDS-PAGE assays in the presence 
and absence of 100mM dithiothreitol (DTT; Sigma-Aldrich, UK) or PNGase (Promega Corporation, 
USA) were used to measure dimerisation and glycosylation status respectively (detailed in 
Kilpatrick et al., 2017). Ligands were stored in 2.5mg/ml protease-free bovine serum albumin 
(BSA; Millipore, USA). Labelling specificity and efficiency was determined using liquid 
chromatography-tandem mass spectrometry (LC-MS).  SDS-PAGE assays in the presence and 
absence of dithiothreitol (DTT; Sigma-Aldrich, UK) or PNGase (Promega Corporation, USA) were 
used to measure dimerisation and glycosylation status respectively (detailed in Kilpatrick et al., 
2017).  
NFAT Luciferase Reporter Gene Assay. 
HEK293T cells stably expressing both wild type VEGFR2 and the Firefly luciferase reporter gene 
ReLuc2P (Promega Corporation, USA) inserted downstream of the NFAT promoter were used to 
monitor NFAT-induced gene transcription following VEGFR2 activation (Carter et al., 2015).  On 
the day of experimentation, cells grown to 95-100% confluency were plated in white-sided 96 well 
plates (Greiner Bio-One, 655089) at 44,000 cells/well, and incubated for 1 hour in 100µl/well serum 
free DMEM/0.1% BSA (37°C/5% CO2). Cells were stimulated in duplicate wells with increasing 
concentrations of VEGF121a-TMR, VEGF165b-TMR or equivalent unlabelled VEGF isoforms 
(synthesised in an identical manner to the fluorescent variant), then incubated for 5 hours at 
37°C/5% CO2. ONE-Glo Luciferase reagent (Promega Corporation, USA) was then added at 
100µl/well and luminescence was measured using a TopCount platereader (Perkin Elmer, UK) 
following a 5 minute delay allowing reagent to react with luciferase and background luminescence 
to subside. 
VEGFR2 Phosphorylation Assay. 
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HEK293T cells stably expressing NanoLuc-VEGFR2 were seeded at 15,000 cells/well in black flat-
bottomed 96-well plates (Greiner Bio-One, 655090) pre-coated with poly-D-lysine (0.01mg/ml in 
PBS). Following 24 hours, cells were serum starved and grown for another 24 hours (37°C/5% 
CO2), with additional 1 hour serum starving step prior to experimentation. For negative control 
wells, cells were pre-incubated for 30 minutes with 1µM cediranib (Sequoia Research Products, 
UK). Cells were then stimulated for 20 minutes with 30nM VEGF165b-TMR or VEGF121a-TMR, 
commercially available VEGF165a, VEGF165b or VEGF121a (R&D Systems) and VEGF165b or 
VEGF121a prepared identically to the fluorescent analogues, in the presence of absence of 
negative control 1µM cediranib. Cells were washed with 100µl/well PBS, fixed with 3% 
paraformaldehyde (PFA)/PBS for 20min at room temperature (RT), washed (3x5min PBS), 
permeabilised with 0.025% Triton-X-100 in PBS, washed (3x5min PBS) and incubated with 3% 
BSA/1% glycine/PBS to reduce non-specific binding (30mins, RT). After washing (3x5min PBS), 
cells were blocked with 10% chick serum in PBS (30min, RT) and incubated at 4°C overnight with 
rabbit monoclonal anti-VEGFR2 phosphoY1212 (Cell Signalling, 2477) diluted 1:200 in 10% chick 
serum/PBS. Cells were washed (3x5min PBS) and incubated in the dark with secondary antibody 
chick anti-rabbit AlexaFluor488 (Thermo Fisher, A21441). Nuclei were stained with 2mg/ml 
H33342 (15min, RT), washed and stored at 4°C in PBS. Cells were imaged using an ImageXpress 
Micro widefield platereader (Molecular Devices, USA) with a 20x objective at 4 sites per well using 
FITC and DAPI filters (exposure 1500ms and 25ms respectively).  
HUVEC Proliferation Assay. 
HUVECs (passage 4-9) were seeded at 5,000 cells/well in black flat-bottomed 96-well plates 
(Greiner Bio-One, 655090) in 10% LVES/Medium 200. Following 24 hours of cell growth at 
37°C/5% CO2, plating medium was replaced with Medium 200 containing 0.1% serum for 24 hours. 
Cells were then stimulated with commercially available VEGF121a or VEGF165b (R&D Systems), 
VEGF121a-TMR or VEGF165b-TMR (Promega Corporation, USA) at 0.3nM, 3nM or 30nM (in 0.1% 
serum/medium), or positive control 3nM VEGF165a (R&D Systems). Following 48 hour stimulation 
at 37°C/5% CO2, cells were washed with 100µl/well PBS, fixed with 3% PFA/PBS (20 minutes, 
room temperature ) and nuclei stained with 2mg/ml H33342 (15 minutes, RT). Nuclei were imaged 
using an ImageXpress Micro widefield platereader (Molecular Devices, USA) with a 4x objective 
using a DAPI filter (4 sites per well, 25ms exposure time).  
Measuring Ligand Binding Using NanoBRET. 
HEKT293 cells stably expressing full-length wild-type VEGFR2, NRP1 or NRP1 Y297A, tagged on 
the N-terminus with the 19kDa luciferase NanoLuc, were seeded 24 hours prior to experimentation 
at 35,000 cells/well on white 96-well clear bottomed plates (Greiner Bio-One, 655089) pre-coated 
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with poly-D-lysine (0.01mg/ml in PBS), and incubated at 37°C/5% CO2. Having identified a natural 
polymorphism (V297I) in the NanoLuc-VEGFR2 construct used previously (Kilpatrick et al., 2017), 
experiments performed with VEGF165a-TMR verified no distinction from wild type VEGFR2 (Figure 
1, Figure 3). Medium was replaced with Hank’s buffered saline solution (HBSS) containing 0.1% 
BSA. For full displacement experiments, cells were co-incubated with increasing concentrations of 
unlabelled ligand (R&D Systems) or vehicle (HBSS/0.1% BSA), as well as fixed concentrations of 
fluorescently labelled VEGF165a-TMR, VEGF165b-TMR or VEGF121a-TMR in duplicate wells 
(0.25nM, 0.5nM, 1nM, 2nM, 3nM). Additional displacement experiments incubated NanoLuc-
VEGFR2 or NanoLuc-NRP1 cells with 3nM VEGF-TMR in the presence and absence of 30nM 
competing unlabelled VEGF. For saturation experiments, increasing concentrations of VEGF165a–
TMR, VEGF165b-TMR or VEGF121a-TMR were added in the presence or absence of a high 
concentration of corresponding unlabelled ligand (100nM, ~100-fold greater than the estimated KD 
value). Following 60min stimulation in the dark at 37°C, the NanoLuc substrate furimazine (final 
concentration 10µM) was added to each well and equilibrated for 5 minutes to enable NanoLuc-
mediated furimazine oxidation and resulting bioluminescence emission. Emissions were recorded 
using the PHERAstar FS platereader (BMG Labtech) using filters measuring NanoLuc emissions 
at 450nm (30nm bandpass), then TMR emissions using a longpass filter at 550nm for NanoLuc-
VEGFR2 cells or 610nm for cells expressing wild type or mutant NanoLuc-NRP1. BRET ratios 
were calculated as fluorescence over luminescence emissions. NanoBRET kinetic experiments 
were performed at 37°C throughout and required furimazine pre-treatment 5 minutes prior to 
addition of VEGF165a-TMR, VEGF165b-TMR or VEGF121a-TMR (1nM to 20nM). BRET ratios were 
then calculated every 30 seconds for up to 120 minutes. 
Live Cell Confocal Imaging. 
HEKT293 cells stably expressing HaloTag-VEGFR2, HaloTag-NRP1 or HaloTag-NRP1 Y297A 
were seeded 48 hours prior to imaging at 20,000 cells/well in 8-well plates (Nunc Lab-Tek, Thermo 
Fisher Scientific) pre-coated with poly-D-lysine (0.01mg/ml in PBS), then replaced with serum free 
DMEM following 24 hours. Cells were treated with 0.5µM membrane impermeant HaloTag Alexa 
Fluor 488 substrate (Promega Corporation, USA) in HBSS/0.1% BSA for 30 min (37°C). Cells were 
then washed twice and replaced with HBSS/0.1% BSA prior to incubation with 10nM VEGF165a-
TMR, VEGF165b-TMR or VEGF121a-TMR in the dark at 37°C. Cells were imaged live using an 
LSM710 confocal microscope fitted with a 63x Pan Apochromat oil objective (1.4NA) using 
Argon488 and Argon 546 laser excitation (3% power), a long pass 540 filter and a pin hole 
diameter of 1 Airy unit. All images were taken at 1024x1024 pixels per frame with 8 averages.  
Fluorescence Correlation Spectroscopy (FCS). 
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Solution based FCS measurements were performed in Nunc LabTek 8-well chambered 
coverglasses (Thermo-Fisher Scientific, UK) using a LSM510 NLO Confocor3 microscope 
equipped with a c-Apochromat 40/1.2NA water immersion objective (Zeiss, Germany). The 
confocal volume was placed 200µm in solution above the surface of the coverglass. Calibration of 
beam paths was performed using 20nM Rhodamine 6G (Diffusion coefficient (D) = 2.8 10-10 m2/s; 
Sigma Aldrich, UK) in high performance liquid chromatography grade water (Chromasolv; Sigma 
Aldrich) with 488nm and 561nm laser lines using 10x10sec reads. A range of VEGF165b-TMR or 
VEGF121a-TMR (2-10nM) solutions were prepared in HBSS/0.1% BSA in the presence or absence 
of 10mM DTT. DTT containing ligand solutions were preincubated for 30min. FCS recordings were 
collected with 2 sets of 10x10secs reads using 561nm laser excitation (20% power; AOTF set to 
10; equivalent to 0.39kW/cm2) with fluorescence emissions collected using a long pass 580 
(LP580) filter.   
Immunofluorescence Labelling.  
For confocal imaging (Figure S3), HUVECs, wild type HEKT293 cells or HEKT293 cells expressing 
NanoLuc-VEGFR2 or NanoLuc-NRP1 were seeded onto poly-D-lysine coated high resolution 
coverslips (Zeiss, Germany; 18mmx18mm, 1.5H) at 300,000 cells/well and grown in 6 well culture 
plates 24 hours prior to experimentation. On the day of the assay, coverslips were transferred to 
humidified wells lined with parafilm and PBS to avoid dryness and washed 3x5min with PBS. Cells 
were fixed with 3% paraformaldehyde (PFA)/PBS for 20min at room temperature (RT), washed 
(3x5min PBS) and incubated with 3% BSA/1% glycine/PBS to reduce non-specific binding 
(30mins, RT). After washing, cells were blocked with 4% chick serum or donkey serum for 
VEGFR2 and NRP1 staining respectively (PBS, 30min, RT). This was then replaced with primary 
antibody diluted 1:200 in 4% serum/PBS and incubated overnight at 4°C (anti-VEGFR1 mAb 
produced in mice, Sigma V4762; anti-VEGFR2 mAb (mouse), Sigma V9134; anti-NRP1 goat pAb 
Santa Cruz 7239). The following day, cells were washed and incubated in the dark with secondary 
antibody diluted 1:500 in 4% serum/PBS for 1 hour at room temperature (VEGFR1 and VEGFR2 
chick anti-mouse AlexaFluor488, Invitrogen A21463; NRP1 donkey anti-goat AlexaFluor546, 
Invitrogen A11056). Coverslips were washed, mounted onto slides using ProLong Diamond 
(Thermo Fisher Scientific), sealed and stored at 4°C. Coverslips were imaged using a Confocal 
Zeiss LSM880 fitted with a 63x Pan Apochromat oil objective (1.4NA) using Argon488 or DPSS561 
laser excitation at 2% laser power with a pinhole diameter of 1 Airy unit. 
To quantify relative receptor expression (Figure S4), HUVECs, wild type HEK293T cells or 
HEK293T cells expressing NanoLuc- and HaloTag- labelled VEGFR2 or NRP1 were seeded at 
25,000 cells/well in black 96-well plates pre-coated with poly-D-lysine (0.01mg/ml in PBS) and 
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grown for 24 hours (37°C/5% CO2). Cells were fixed with 3% PFA/PBS then followed an identical 
immunofluorescence staining protocol as above in 96-well plates with VEGFR2 mouse mAb 
(Sigma V9134) and NRP1 goat pAb (Santa Cruz 7239). Having labelled with respective secondary 
antibodies, cells were washed with PBS, nuclei were stained with 2mg/ml H33342 (15 minutes, 
RT), washed and stored in PBS at 4°C. Cells were imaged using an ImageXpress Micro widefield 
platereader with a 20x objective at 4 sites per well, with a FITC or TRITC filter for VEGFR2 or 
NRP1 respectively (500ms exposure time) and a DAPI filter imaging nuclei (25ms exposure time). 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Data Analysis. 
All data are presented as mean ± S.E.M. and were analysed using GraphPad Prism 7.02 (San 
Diego, CA, USA). Equilibrium binding and functional assays were analysed as described in 
Kilpatrick et al. (2017).  A power calculation was performed to confirm sample number for statistical 
comparisons of pKi values obtained with different fluorescent ligands.  This was done on the basis 
of 5 separate experiments with the anticipated standard deviation obtained in similar experiments 
and a calculation of the statistical power to detect a significant change of pKi of 0.3 log units. This 
yielded a power of 0.99, i.e. there was a 99% chance of detecting a significant change in pKi value 
of 0.3 log units. Statistical analyses using one-way ANOVA are described in the corresponding 
figure legends or within the text. Significance was defined as p<0.05. 
High Content Imaging.  
Images obtained with the ImageXpress Micro widefield platereader at 4 sites per well were 
quantified using MetaXpress 2.0 (Molecular Devices, USA). Nuclei were quantified with diameter 
5-25µm and 100 graylevel intensity above background. VEGFR2 phosphorylation was quantified 
(Figure 1d,e) using a granularity algorithm, granules were defined as 6-12µm diameter with a 
graylevel intensity of 50 above background. Granularity was quantified per cell, baseline-corrected 
to non-specific binding (secondary antibody only) and normalised to cediranib-treated wells (0%) 
and response to 30nM VEGF165a (100%). Quantifying relative receptor expression (Figure S4) 
using a multiwavelength cell scoring algorithm, regions were defined as 2-15µm in size. Due to 
distinctions in secondary antibodies, VEGFR2 (FITC) was defined as intensity over 200 graylevels 
and NRP1 (TRITC) over 50 graylevels. Fluorescence was quantified as integrated intensity per cell 
and baseline-corrected per experiment to non-specific fluorescence (secondary antibody only). 
FCS Autocorrelation Analysis. 
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Autocorrelation analysis was performed using Zen 2010 software (Zeiss, Germany) with all traces 
fit using a single one component, free 3D Brownian diffusion model, with a pre-exponential 
included to account for the triplet state of the fluorophore. 
DATA AND SOFTWARE AVAIALBILITY 
GraphPad Prism 7.02 (San Diego, CA, USA) was used to analyse the quantified data and produce 
the graphs. Zen 2010 (Zeiss; Germany) was used to perform autocorrelation analysis for FCS. 
MetaXpress 2.0 (Molecular Devices, USA) was used to quantify VEGFR2 phosphorylation and 
receptor expression labelled with immunofluorescence following high content imaging on the 
widefield platereader. 
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 KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse monoclonal anti-VEGFR1 Sigma Aldrich  Cat# V4762 
RRID:AB_477
622 
Mouse monoclonal anti-VEGFR2 Sigma Aldrich Cat# V9134 
RRID:AB_477
630 
Goat polyclonal anti-Neuropilin-1 Santa Cruz Cat# SC7239 
RRID:AB_215
0835 
Rabbit monoclonal anti-VEGFR2 
phosphoY1212 
Cell Signalling Technology Cat# 2477S 
RRID:AB_331
374  
Chemicals, Peptides, and Recombinant Proteins 
VEGF165a R&D Systems (Abingdon, UK) Cat# 293-VE 
VEGF165b R&D Systems (Abingdon, UK) Cat# 3045-VE 
VEGF121a R&D Systems (Abingdon, UK) Cat# 4644-VS 
VEGF145a R&D Systems (Abingdon, UK) Cat# 7626-VE 
VEGF189a R&D Systems (Abingdon, UK) Cat# 8147-VE 
VEGF111a R&D Systems (Abingdon, UK) Cat# 5336-VE 
VEGF-Ax R&D Systems (Abingdon, UK) Cat# 9018-VE 
HaloTag AlexaFluor 488 membrane impermeant 
substrate  
Promega Corporation (Wisconsin, 
USA) 
Cat# G1002 
bisBenzimide H 33342 trihydrochloride Sigma Aldrich Cat# B2261 
Formaldehyde solution 4%  Sigma Aldrich Cat# F8775 
Cediranib  Sequoia Research Products Cat# 
SRP01883c 
Chromasolv Sigma Aldrich Cat# 34877 
Rhodamine 6G Sigma Aldrich Cat# R4127 
Triton-X-100 (laboratory grade) Sigma Aldrich Cat# X100 
DTT 1,4-Dithiothreitol Sigma Aldrich Cat# DTT-RO 
PNGase F Promega Corporation (Wisconsin, 
USA) 
Cat# V4831 
Protease-free bovine serum albumin  Milpore  Cat# 126609 
Protease-free bovine serum albumin  Sigma Aldrich Cat# 
03117332001 
Secondary chick anti-mouse Invitrogen Cat# A21463 
Secondary donkey anti-goat Invitrogen Cat# A11056 
Secondary chick anti-rabbit AlexaFluor-488 ThermoFisher Scientific, USA Cat# A-21441 
Chicken serum Sigma Aldrich Cat# C5405 
Donkey serum Sigma Aldrich Cat# D9663 
ProLong Gold antifade reagent ThermoFisher Scientific, USA Cat# P10144 
Dulbecco’s Modified Eagle’s Medium Sigma Aldrich Cat# D6429 
Fetal Bovine Serum  Sigma Aldrich Cat# F2442 
Medium 200 (Gibco) ThermoFisher Scientific, USA Cat# M-200-
500 
Large Vessel Endothelial Supplement (LVES 
50x) (Gibco) 
ThermoFisher Scientific, USA Cat# 
A1460801 
Poly-D-Lysine hydrobromide Sigma Aldrich Cat# P6407 
Key Resource Table
 Dulbecco’s Phosphate Buffered Saline (DPBS) Sigma Aldrich Cat# D8537 
Trypsin-EDTA solution x10 Sigma Aldrich Cat# T4174 
Critical Commercial Assays 
HaloTag Mammalian Protein Detection and 
Purification System 
Promega Corporation (Wisconsin, 
USA) 
Cat# G6795 
ONE-GloTM Luciferase Promega Corporation (Wisconsin, 
USA) 
Cat# E6120 
Nano-Glo luciferase assay system (Furimazine) Promega Corporation (Wisconsin, 
USA) 
Cat# N1130 
Experimental Models: Cell Lines 
Human: GloResponse™ NFAT-RE-luc2P 
HEK293 cell line (female) 
Promega Corporation (Wisconsin, 
USA) 
Cat# E8510 
Human: HUVEC cells (newborn male, single 
donor) 
ThermoFisher Scientific Cat# C0035C. 
Lot number: 
1606186. 
Human: HEK293T cells (female) ATCC (Virginia, USA) Cat# CRL-
3216 
Recombinant DNA 
NanoLuc-VEGFR2 Promega Corporation (Wisconsin, 
USA) 
Custom 
synthesis 
NanoLuc-NRP1 Promega Corporation (Wisconsin, 
USA) 
Custom 
synthesis 
NanoLuc-NRP1 Y297A Promega Corporation (Wisconsin, 
USA) 
Custom 
synthesis 
HaloTag-VEGFR2 Promega Corporation (Wisconsin, 
USA) 
Custom 
synthesis 
HaloTag-NRP1  Promega Corporation (Wisconsin, 
USA) 
Custom 
synthesis 
HaloTag-NRP1 Y297A Promega Corporation (Wisconsin, 
USA) 
Custom 
synthesis 
VEGF165a Gene Dynamics LLC (Oregon, USA) Custom 
synthesis 
VEGF165b Gene Dynamics LLC (Oregon, USA) Custom 
synthesis 
VEGF121a Gene Dynamics LLC (Oregon, USA) Custom 
synthesis 
pFN21 HaloTag CMV Flexi Vector (modified to 
contain a IL-6 secretion sequence and a 
EPTTEDLYFQCDN linker sequence)  
Promega Corporation (Wisconsin, 
USA) 
Cat# G2821 
Software and Algorithms 
GraphPad Prism 7.02 GraphPad Software, La Jolla 
California USA 
www.graphpa
d.com 
Zen 2010 Zeiss, Germany www.zeiss.co
m 
MetaXpress  Molecular Devices, USA www.molecula
rdevices.com 
Other 
Black 96-well plates  Greiner Bio-One Cat# 655090 
White 96-well plates Greiner Bio-One Cat# 655098 
8-well plates  Nunc Lab-Tek, Thermo Fisher 
Scientific 
Cat# 155411 
 Coverslips (18x18mm; 1.5H) Zeiss, Germany Cat# 474030-
9000-000 
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Real-time ligand binding to VEGFR2 and Neuropilin-1 with fluorescent VEGF-A isoforms 
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Figure S1.  LC-MS/MS analysis of VEGF165b-TMR digested with multiple proteases. (Relates 
to Figure 1). (a) Peptide coverage achieved by digestion with trypsin, LysC/GluC and elastase 
proteases. The N-terminal cysteine is marked in red. None of the other 14 residues presented in 
the VEGF165b protomer were labelled.  Protein identity was confirmed by searching the MS/MS 
spectra using the Mascot search engine (Matrix Science Inc, Boston, USA) against a human 
database (SwissProt). The highest scoring hit was the VEGF sequence.  (b) LC-MS/MS analysis of 
the peptide containing the N terminal cysteine (CDNAPMAEGGGQNHHEVVK) derived from 
VEGF165b-TMR (right panel)  and VEGF165b (left panel) that were purified in the same manner and 
digested with trypsin protease.  Retention times and mono-isotopic masses are given in 
Supplementary Table 1. (c) Fluorescence SDS-PAGE analysis of VEGF165b-TMR (Eex=532 nm; 
Eem=580 nm) in the presence or absence of 100mM DTT and with or without deglycosylation by 
PNGase.  (d) VEGF165b-TMR concentration determined using fluorescence correlation 
spectroscopy (FCS) in the presence or absence of 10mM DTT. N=4-6 separate experiments. 
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Figure S2.  LC-MS/MS analysis of VEGF121a-TMR digested with multiple proteases. (Relates to 
Figure 1). (a) Peptide coverage achieved by digestion with trypsin, LysC/GluC and elastase 
proteases. The N-terminal cysteine is marked in red. None of the other 8 residues presented in the 
VEGF121a protomer were labelled.  Protein identity was confirmed by searching the MS/MS spectra 
using the Mascot search engine (Matrix Science Inc, Boston, USA) against a human database 
(SwissProt). The highest scoring hit was the VEGF sequence.  (b) LC-MS/MS analysis of the peptide 
containing the N terminal cysteine (CDNAPMAEGGGQNHHEVVK) derived from VEGF121a-TMR 
(right panel) and VEGF121a (left panel) that were purified in the same manner and digested with 
trypsin protease.  Retention times and mono-isotopic masses are given in Supplementary Table 1. (c) 
Fluorescence SDS-PAGE analysis of VEGF121a-TMR (Eex=532 nm; Eem=580 nm) in the presence or 
absence of 100mM DTT and with or without deglycosylation by PNGase.  (d) VEGF121a-TMR 
concentration in the presence or absence of 10mM DTT quantified using fluorescence correlation 
spectroscopy (FCS).  N=3-4 separate experiments.  
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Figure S3.  Immunofluorescence labelling of VEGFR1, VEGFR2 and Neuropilin-1 (NRP1) 
expression in HEK293 cells and HUVECs. (Relates to Figure 2). Immunofluorescence staining 
for either (A) VEGFR1 (green), (B) VEGFR2 (green) or (B) Neuropilin-1 (yellow), alongside phase 
contrast images, in fixed cells on coverslips imaged using the Zeiss Confocal LSM880 (63X 
magnification). Scale bars shown as 20μm and images are representative of n=3. 
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Figure S4.  Relative expression of VEGFR2 and NRP1 in endothelial and transfected cell 
lines. (Relates to Figure 2). Quantified immunofluorescence staining for (A) VEGFR2 or (B) 
Neuropilin-1, in fixed HUVEC or HEK293T cells imaged in 96-well plates using ImageXpress Micro 
(20x magnification). Fluorescence was quantified on a per cell basis and baseline-corrected for 
non-specific fluorescence per experiment (secondary antibody only). Data shown as mean±S.E.M.  
from 5 independent experiments.  
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Table S1. (Relates to Figure 1). 
LS-MS/MS profiles for unlabelled peptide fragments obtained following protease digestion of VEGF or VEGF-TMR. 
 
Peptide sequence Digest VEGF 
isoform 
Mass/charge 
(m/z) 
Charge 
 (z) 
Mass 
[M+H]*  
Retention 
Time 
(Min)  
Peak 
Area 
Sample % % 
Labelled 
CDNAPMAEGGGQNHHEVVK  Trypsin VEGF165b 498.97 4 1992.89 10.5 1.36E+08 Labelled 2.9 97.1 
CDNAPMAEGGGQNHHEVVK Trypsin VEGF165b 498.97 4 1992.89 10.5 4.66E+09 Unlabelled 100 n/a  
CDNAPMAEGGGQNHHEVVK Trypsin VEGF121a 498.97 4 1992.89 10.5 6.20E+08 Labelled 6.1 93.9 
CDNAPMAEGGGQNHHEVVK Trypsin VEGF121a 498.97 4 1992.89 10.3 1.01E+10 Unlabelled 100  n/a 
CDNAPMAE  LysC/GluC VEGF165b 425.66 2 850.31 13.7 5.26E+06 Labelled 3.5 96.5 
CDNAPMAE LysC/GluC VEGF165b 425.66 2 850.31 13.6 1.52E+08 Unlabelled 100  n/a 
CDNAPMAE LysC/GluC VEGF121a 425.66 2 850.31 13.5 1.14E+07 Labelled 1.2 98.8 
CDNAPMAE LysC/GluC VEGF121a 425.66 2 850.31 13.6 9.23E+08 Unlabelled 100  n/a 
 
LS-MS/MS profiles for unlabelled peptide fragments obtained following protease digestion of VEGF or VEGF-TMR.  The labeling efficiency of VEGF165b-TMR 
or VEGF121a-TMR was determined by comparing the integrated peak areas of the unmodified proteolytic peptides in the labelled and unlabelled samples that 
were digested with trypsin or LysC/GluC. The analysis indicated 94-99% labelling efficiency. *Mono-isotopic mass at a single charge assuming the peptide 
takes up a single proton. Mono-isotopic mass [M+H] is calculated as (m/z)*z – (z-1).  
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Table S2 (relates to Figure 1). 
 
LS-MS/MS profiles for labelled peptide fragments obtained following protease digestion of VEGF or VEGF-TMR. 
 
Peptide sequence Digest VEGF 
isoform 
Mass/charge 
 (m/z) 
Charge 
(z)  
Mass of 
labelled 
peptide   
[M+H]* 
Mass of 
unlabelled 
peptide  
[M+H]* 
Mass 
Difference  
CDNAPMAEGGGQNHHEVVK  Trypsin VEGF165b 937.39 3 2810.16 1992.89 817.27 
CDNAPMAEGGGQNHHEVVK  Trypsin VEGF121a 937.39 3 2810.16 1992.80 817.27 
CDNAPMAE LysC/GluC VEGF165b 834.30 2 1667.59 850.31 817.28 
CDNAPMAE LysC/GluC VEGF121a 834.30 2 1667.59 850.31 817.28 
 
LS-MS/MS profiles for  labelled peptide fragments obtained following protease digestion of VEGF or VEGF-TMR.  Observed mass of the 
labelled peptides containing the N-terminal cysteine confirmed a mass increase of 817 Da due to covalent attachment of the 6-TMR-PEG-CBT.  
*Mono-isotopic mass at a single charge assuming the peptide takes up a single proton. *Mono-isotopic mass [M+H] is calculated as (m/z)*z – 
(z-1). 
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Table S3. Competition binding pKi values for VEGF-A isoforms binding to VEGFR2 and NRP1 (relates to Figures 3 and 4). 
 
 
NanoLuc-VEGFR2 NanoLuc-VEGFR2 NanoLuc-VEGFR2 NanoLuc-NRP1 
VEGF isoform VEGF165a-TMR VEGF165b-TMR VEGF121a-TMR VEGF165a-TMR 
VEGF-Ax 9.20 ± 0.02 9.57 ± 0.03 9.65 ± 0.06 ND 
VEGF165a 9.57 ± 0.04 9.73 ± 0.09 9.54 ± 0.05 9.54 ± 0.21 
VEGF165b 9.07 ± 0.02 9.61 ± 0.06 9.28 ± 0.10 ND 
VEGF121a 9.30 ± 0.06 9.58 ± 0.18 9.31 ± 0.08 ND 
VEGF145a 8.83 ± 0.03 8.92 ± 0.08 8.82 ± 0.08 7.82 ± 0.15 
VEGF189a 9.13 ± 0.03 8.92 ± 0.03 9.06 ± 0.09 8.60 ± 0.14 
VEGF111a 9.66 ± 0.13 9.89 ± 0.15 9.98 ± 0.05 ND 
 
Summary of binding affinities (pKi) of unlabelled VEGF-A isoforms determined from inhibition of the binding of VEGF165a-TMR, VEGF165b-TMR 
or VEGF121a-TMR to NanoLuc-VEGFR2 and NanoLuc-NRP1. Data are expressed as mean ± S.E.M determined from 5 independent 
experiments. ND = not determined due to lack of significant inhibition of binding with 30nM unlabelled VEGF isoform. 
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